imgn151
mAbexperimentalADC
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 6, 2022 (NCT05527184)
Timeline
Indications
Mechanism of action
- Folate receptor alphaBINDING AGENT
FOLR1 binding agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07024784 | Phase 2 | Jul 30, 2025 | AbbVie |
| NCT05527184 | Phase 1 | Dec 6, 2022 | Immunogen |
Showing 2 of 2 trials
Page 1 / 1